{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:13:00Z","timestamp":1793142780476,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004791","name":"Target Corporation","doi-asserted-by":"publisher","award":["101020342"],"award-info":[{"award-number":["101020342"]}],"id":[{"id":"10.13039\/100004791","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018703","name":"European Innovation Council","doi-asserted-by":"publisher","award":["635342"],"award-info":[{"award-number":["635342"]}],"id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21091"],"award-info":[{"award-number":["21091"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2022CHB9BA"],"award-info":[{"award-number":["2022CHB9BA"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105892","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:58:04Z","timestamp":1764694684000},"page":"105892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6324","authenticated-orcid":false,"given":"E.","family":"Elez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-2846","authenticated-orcid":false,"given":"S.","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-0409","authenticated-orcid":false,"given":"A.","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-5415","authenticated-orcid":false,"given":"J.","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ciardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-2279","authenticated-orcid":false,"given":"N.","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Huijberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rosell\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wilmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9419-6232","authenticated-orcid":false,"given":"R.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"de Schaetzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bernards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2818-5487","authenticated-orcid":false,"given":"V.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garc\u00eda-Galera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Alemany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Piris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chavarr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105892_bib1","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3389\/fimmu.2019.01816","article-title":"Is there a place for immunotherapy for metastatic microsatellite stable colorectal cancer?","volume":"10","author":"Ghiringhelli","year":"2019","journal-title":"Front Immunol"},{"issue":"7407","key":"10.1016\/j.esmoop.2025.105892_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105892_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc.2016.126","article-title":"Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer","volume":"17","author":"Dienstmann","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"7683","key":"10.1016\/j.esmoop.2025.105892_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105892_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105892_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105892_bib7","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.3390\/cancers14204974","article-title":"Immune-checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) patients beyond microsatellite instability","volume":"14","author":"Borelli","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"26","key":"10.1016\/j.esmoop.2025.105892_bib8","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105892_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/1078-0432.CCR-18-1984","article-title":"Intertumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch-repair-deficient colon cancers: implications for prognosis","volume":"25","author":"Yoon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105892_bib10","first-page":"123","article-title":"Microsatellite stable colorectal cancer with an immunogenic phenotype: challenges in diagnosis and treatment","volume":"19","author":"Saller","year":"2020","journal-title":"Clin Colorectal Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105892_bib11","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.esmoop.2025.105892_bib12","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-22-3964","article-title":"Transcriptomic signatures of MSI-high metastatic colorectal cancer predict efficacy of immune checkpoint inhibitors","volume":"29","author":"Gallois","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105892_bib13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105892_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-021-01034-0","article-title":"The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials","volume":"14","author":"Saeed","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105892_bib15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4049\/jimmunol.181.1.346","article-title":"Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma","volume":"181","author":"Kusmartsev","year":"2008","journal-title":"J Immunol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105892_bib16","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1158\/1078-0432.CCR-07-0374","article-title":"A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism","volume":"13","author":"Manning","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105892_bib17","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105892_bib18","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"10189","key":"10.1016\/j.esmoop.2025.105892_bib19","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105892_bib20","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105892_bib21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.4092","article-title":"A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency","volume":"228","author":"Tian","year":"2012","journal-title":"J Pathol"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105892_bib22","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1158\/1078-0432.CCR-08-1431","article-title":"DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers","volume":"14","author":"Jorissen","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105892_bib23","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","article-title":"The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105892_bib24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-019-6073-7","article-title":"Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy","volume":"19","author":"Bilen","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105892_bib25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105892_bib26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105892_bib27","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105892_bib28","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2024.42.16_suppl.3503","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): expanded efficacy analysis from CheckMate 8HW","volume":"42","author":"Lenz","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105892_bib29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105892_bib30","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1007\/s00262-021-02986-5","article-title":"A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186","volume":"70","author":"Herting","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105892_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105892_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100559","article-title":"MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorectal cancer","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105892_bib33","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105892_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105892_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00384-024-04654-3","article-title":"PD-1\/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review","volume":"39","author":"Wu","year":"2024","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105892_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008210","article-title":"Multiomic molecular characterization of the response to combination immunotherapy in MSS\/pMMR metastatic colorectal cancer","volume":"12","author":"Takei","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105892_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105892_bib38","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2217\/imt.12.99","article-title":"The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies","volume":"4","author":"Mazzolini","year":"2012","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105892_bib39","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.26938","article-title":"Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice","volume":"59","author":"Dolina","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.esmoop.2025.105892_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.812210","article-title":"Novel use of low-dose radiotherapy to modulate the tumor microenvironment of liver metastases","volume":"12","author":"He","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105892_bib41","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.3390\/cancers12123650","article-title":"TGF-beta mediated immune evasion in cancer-spotlight on cancer-associated fibroblasts","volume":"12","author":"Ghahremanifard","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:25:47Z","timestamp":1773854747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017612"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105892","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105892"}}